EnVivo Pharmaceuticals to Highlight Clinical Stage Program at Neuroscience 2011

EVP-6124 Mechanism-Based Approach to be Discussed in Satellite Symposium

WATERTOWN, Mass.--(BUSINESS WIRE)-- EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it has been selected to discuss its lead program EVP-6124, a nicotinic alpha-7 agonist, at the Society for Neuroscience 41st Annual Meeting. Neuroscience 2011 will be held Nov. 12-16, 2011 at the Walter E. Washington Convention Center in Washington D.C.

Presentation information is as follows:

Satellite Symposium: Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research & Clinical Science (nAChR2011)
Gerhard Koenig, Ph.D., senior vice president, research and chief scientific officer of EnVivo, will discuss the pharmacology and mechanism-based approach of EVP-6124 in schizophrenia and Alzheimer’s disease. EnVivo recently announced positive topline Phase 2b data for EVP-6124 in schizophrenia, and plans to present a comprehensive Phase 2b data analysis at an upcoming scientific meeting later this year. EVP-6124 is also currently being evaluated in a Phase 2b clinical trial in Alzheimer’s disease, with results expected to be announced in early 2012.

The discussion, “Utility of an Alpha-7 Nicotinic Agonist EVP-6124 in Schizophrenia and Alzheimer’s Disease – Update on a Mechanism-based Approach,” will be held Thursday, Nov. 10, from 3 to 3:30 p.m.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, Inc. and its subsidiaries (“EnVivo Pharmaceuticals” or “EnVivo”) are dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS). EnVivo Pharmaceuticals, Inc. is a biotech company located in Watertown, Mass. The company’s focus is on building an integrated company and it is working to convert its broad pipeline into a range of CNS therapies that leverage novel mechanisms of action by altering the progression of disease and providing improvement in cognitive and overall function. EnVivo’s lead product is an alpha-7 nicotinic acetylcholine receptor agonist that has successfully completed a Phase 2b clinical trial in schizophrenia and is currently in an ongoing Phase 2b clinical trial for the treatment of cognitive impairment in Alzheimer’s disease. EnVivo’s other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) in preparation for Phase 2 studies, a Gamma Secretase Modulator program in Phase 1 and several preclinical programs, including a potent and selective PDE10 inhibitor program expected to enter the clinic in early 2012. For more information about EnVivovisit www.envivopharma.com.



CONTACT:

Pure Communications
Sheryl Seapy, 949-608-0841

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.